Evidence map›Paper›PMID 41757162›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Longitudinal peripheral blood multi-omic profiling in seropositive individuals identifies immune endotypes and predictive models for future rheumatoid arthritis conversion.

Jun Inamo, Aleksandra Bylinska, Miles Smith, Lauren Vanderlinden, Christian Wright, Tayte Stephens, Marie L Feser, Christopher C Striebich, James R O'Dell, Jeffrey A Sparks and 15 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Jun InamoDivision of Rheumatology, University of Colorado School of Medicine, Aurora, CO, United States of America.ORCID 0000-0002-9927-7936
Aleksandra BylinskaArthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States of America.
Miles SmithArthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States of America.
Lauren VanderlindenDivision of Rheumatology, University of Colorado School of Medicine, Aurora, CO, United States of America.
Christian WrightArthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States of America.
Tayte StephensArthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States of America.
Marie L FeserDivision of Rheumatology, University of Colorado School of Medicine, Aurora, CO, United States of America.
Christopher C StriebichDivision of Rheumatology, University of Colorado School of Medicine, Aurora, CO, United States of America.
James R O'DellUniversity of Nebraska Medical Center, Omaha, NE, USA.
Jeffrey A SparksMass General Brigham, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-5556-4618
John M DavisDivision of Rheumatology, Mayo Clinic, Rochester, MN, USA.
Jonathan GrafUniversity of California San Francisco, San Francisco, CA, USA.
Maureen A McMahonUniversity of California Los Angeles, Los Angeles, CA, USA.
E Blair SolowUT Southwestern Medical Center, Dallas, TX, USA.
Lindsy J ForbessCedars-Sinai Medical Center, Los Angeles, CA, USA.
Athan N TiliakosEmory University, Atlanta, GA, USA.
David A FoxUniversity of Michigan, Ann Arbor, MI, USA.
Maria I DanilaUniversity of Alabama at Birmingham, Birmingham, AL, USA.
Diane Lewis HorowitzNorthwell Health, New Hyde Park, NY, USA.
Jonathan KayUMass Chan Medical School, Worcester, MA, USA.
Judith A JamesArthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States of America.
V Michael HolersDivision of Rheumatology, University of Colorado School of Medicine, Aurora, CO, United States of America.
Kevin D DeaneDivision of Rheumatology, University of Colorado School of Medicine, Aurora, CO, United States of America.
Joel M GuthridgeArthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States of America.ORCID 0000-0002-9308-237X
Fan ZhangDivision of Rheumatology, University of Colorado School of Medicine, Aurora, CO, United States of America.ORCID 0000-0002-6102-2970

Funding

Regulation of B cell Responses in SLE and Other Autoimmune DiseasesU19AI110483 · NIAID · EMORY UNIVERSITY · PI JEREMY M. BOSS · 2014 to 2026
$76.6M
Tracking and Evaluation CoreU54GM104938 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Janis E Campbell · 2013 to 2026
$68.2M
Colorado Clinical and Translational Sciences Institute (CCTSI)UM1TR004399 · NCATS · UNIVERSITY OF COLORADO DENVER · PI JANINE A HIGGINS, RONALD J. SOKOL · 2023 to 2026
$30.7M
Joint Biology Consortium Resource-based CenterP30AR070253 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Peter A Nigrovic, Jeffrey Andrew Sparks · 2016 to 2026
$9.4M
Oklahoma Rheumatic Disease Research Cores Center (Overall Application)P30AR073750 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JUDITH A JAMES · 2018 to 2026
$8.5M
Core 2 - Mucosal Immunobiology Core (MIC)P30AR079369 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI Vernon Michael Holers · 2021 to 2026
$4.7M
Rheumatoid Arthritis-Related Autoantibodies, Articular Inflammation, and RA-Associated Interstitial Lung DiseaseR01AR077607 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI SPARKS, JEFFREY ANDREW · 2021 to 2025
$3.7M
Oklahoma ACE: Molecular Destruction of Autoimmune Disease to Aid Clinical Trail SuccessUM1AI144292 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JUDITH A JAMES · 2019 to 2026
$3.3M
Immunologic and Clinical Sequelae after COVID-19 in Patients with Systemic Autoimmune Rheumatic DiseasesR01AR080659 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Jeffrey Andrew Sparks · 2023 to 2026
$2.9M
Deciphering Complement-Dependent Macrophage Phenotypes in Human Autoimmune ArthritisR01AR085156 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI FAN ZHANG · 2025 to 2026
$766k
Colorado Autoimmunity Center of ExcellenceUM1AI110503 · NIAID · UNIVERSITY OF COLORADO DENVER · PI HOLERS, VERNON MICHAEL · 2014 to 2018
$543k
NCATS NIH HHS UM1 TR004399NIAID NIH HHS U19 AI110483NIAID NIH HHS UM1 AI110503NIAID NIH HHS UM1 AI144292NIAMS NIH HHS P30 AR070253NIAMS NIH HHS P30 AR073750NIAMS NIH HHS P30 AR079369NIAMS NIH HHS R01 AR077607NIAMS NIH HHS R01 AR080659NIAMS NIH HHS R01 AR085156NIGMS NIH HHS U54 GM104938
6 · The paper itself

Abstract

Individuals who have serum elevations of anti-cyclic citrullinated protein (anti-CCP) antibodies are at risk for developing rheumatoid arthritis (RA), yet immunologic factors that lead to a transition from pre- to clinical RA remain unclear. Here, we used materials from anti-CCP antibody-positive individuals enrolled in a clinical trial that evaluated the efficacy of hydroxychloroquine to prevent clinical RA, and performed multi-modal single-cell profiling (transcriptome, surface proteins, T/B-cell receptor sequencing, and chromatin accessibility) on samples obtained at baseline and at RA onset in those who developed clinical RA (Converters) or follow-up point in matched Nonconverters. At both baseline and follow-up, Converters had expansions of peripheral helper T (Tph) cells and CD8

Identifiers

PMID41757162
PMCPMC12934891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.